Tumor Targeting Agents for Neutron Capture Therapy

  • A. H. Soloway
  • F. Alam
  • R. F. Barth
  • A. K. M. Anisuzzaman
  • B. V. Bapat
Part of the Basic Life Sciences book series (BLSC, volume 54)


The development of compounds for use as delivery agents in the treatment of cancer by neutron capture therapy has largely focused on the use of boron-10 even though there are other nuclides having higher capture cross section values for thermal neutrons. The major reasons are: (1) it is nonradioactive and comprises approximately 20% of naturally occurring boron; (2) boron-10 enriched materials are readily available commercially; (3) the products of the fission reaction are largely high LET recoiling 7Li and 4He (alpha) nuclei; (4) the pathlength of these particles is such that they are confined to a radius approximating the diameter of a single cell; and (5) the chemistry of boron is such that it may be incorporated into a multitude of different stable chemical structures.


Boron Atom Boron Neutron Capture Therapy Relative Biological Effectiveness Brookhaven National Laboratory Boron Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. H. Knoth, J. C. Sauer, D. C. England, W. R. Hertler, and E. L. Muetterties, J. Am. Chem. Soc., 86: 3973 (1964).CrossRefGoogle Scholar
  2. 2.
    A. H. Soloway, H. Hatanaka, and M. A. Davis, “Penetration of Brain and Brain Tumor. VII. Tumor-Binding Sulfhydryl Boron Compounds,” J. Med. Chem., 10: 714 (1967).PubMedCrossRefGoogle Scholar
  3. 3.
    Y. Hayashi, H. Furukawa, Y. Kawano, M. Matsuwa, A. Harihara, S. Aratri, Y. Muraoka, Y. Maeda, T. Yamashita, and M. Muto, “Toxicity of Sodium Monomercaptoundecahydro-closo-dodecaborate by Single Intravenous Inspection,” Research Report from the Shionogi Research Laboratory (Privileged Communication).Google Scholar
  4. 4.
    H. Hatanaka, K. Amano, H. Kanemitsu, I. Ikeuchi, and T. Yoshizki, “Boron Uptake by Human Brain Tumors and Quality Control of Boron Compounds,” in Boron-Neutron Capture Therapy for Tumors, H. Hatanaka, ed., Chapter V, Nishimura Co., Ltd., Niigata, Japan, p. 77 (1986).Google Scholar
  5. 5.
    G. C. Finkel, C. E. Polotti, R. G. Fairchild, D. N. Slatkin, and W. H. Sweet, J. Neurosurg., 24: 6 (1989).CrossRefGoogle Scholar
  6. 6.
    H. Hatanaka and Y. Urano, “Eighteen Autopsy Cases of Malignant Brain Tumors Treated by Boron-Neutron Capture Therapy between 1968 and 1985,” in Boron-Neutron Capture Therapy for Tumors, H. Hatanaka, ed., Chapter XXVI, Nishimura Co., Ltd., Niigata, Japan, p. 381 (1986).Google Scholar
  7. 7.
    F. Alam, A. H. Soloway, and R. F. Barth, “Boronation of Antibodies with Mercaptoundecahydro-closo-dodecaborate (2-) Anion for Potential Use in Boron Neutron Capture Therapy,” Intl. J. Rad. Appl. and Instrumentation, Part A, 38: 503 (1987).CrossRefGoogle Scholar
  8. 8.
    O. W. Press, J. A. Hansen, A. Farr, and P. J. Martin, Cancer Res., 48: 2249 (1988).PubMedGoogle Scholar
  9. 9.
    D. Joel, D. Slatkin, R. Fairchild, P. Micca, and M. Nawrocky, “Pharmacokinetics and Tissue Distribution of the Sulfhydryl Boranes (Monomer and Dimer) in Glioma-Bearing Rats,” Strahlenther. Onkol., 165 (2/3): 167 (1989).PubMedGoogle Scholar
  10. 10.
    G. R. Wellum, E. I. Tolpin, A. H. Soloway, and A. Kaczmarczyk, “Synthesis of µ-Disulfido-bis(undecahydro-closo-dodecaborate) (4-) and of a Derived Free. Radical,” Inorg. Chem., 16: 2120 (1977).CrossRefGoogle Scholar
  11. 11.
    Y. Mishima, Pigment Cell, 1: 215 (1973).Google Scholar
  12. 12.
    J. A. Coderre, J. D. Glass, R. G. Fairchild, P. L. Micca, and J. Kalef-Ezra, “Boronophenylalanine for Neutron Capture Therapy,” Strahlenther. Onkol., 165 (2/3): 215 (1989).PubMedGoogle Scholar
  13. 13.
    H. R. Snyder, A. J. Reedy, and W. J. Lennarz, J. Am. Chem. Soc., 80: 835 (1958).CrossRefGoogle Scholar
  14. 14.
    B. F. Spielvogel, A. Sood, I. H. Hall, R. G. Fairchild, and P. L. Micca, “Synthesis, Antineoplastic Activity and Bio-Distribution of Boron Analogues of Amino Acids and Related Compounds,” Strahlenther. Onkol., 165 (2/3): 123 (1989).PubMedGoogle Scholar
  15. 15.
    W. Tjarks and D. Gabel, “Synthesis of Boronated Thioureas for Neutron Capture Therapy,” Third Int. Symp. on Neutron Capture Therapy, Bremen, FRG, 31 May - 3 June 1988.Google Scholar
  16. 16.
    R. G. Fairchild, S. Packer, D. Greenberg, P. Som, A. B. Brill, I. Frank, and W. P. McNally, Cancer Res., 42: 5126 (1982).PubMedGoogle Scholar
  17. 17.
    F. Alain, B. V. Bapat, A. H. Soloway, R. F. Barth, N. Mafune, and D. M. Adams, “Boronated Compounds for Neutron Capture Therapy,” Strahlenther. Onkol., 165 (2/3): 121 (1989).Google Scholar
  18. 18.
    S. B. Kahl. Kahl, “Present Developments in the Synthesis and Isolation of Atropisomers of Porphyrinic Carburanyl Anilides,” Second Int. Symp. on Neutron Capture Therapy, Tokyo, 1985, H. Hatanaka, ed., Nishimura Co., Ltd., Niigata, Japan (1986).Google Scholar
  19. 19.
    R. F. Schinazi, B. H. Laster; R. G. Fairchild, and W. H. Prusoff, “Synthesis and Biological Activity for a Boron-Containing Pyrimidine Nucleoside,” First Int. Symp. on Neutron Capture Therapy, Cambridge, MA, 1983, R. G. Fairchild and G. L. Brownell, eds., Brookhaven National Laboratory, BNL-51730, p.260 (1984).Google Scholar
  20. 20.
    R. F. Barth, N. Mafune, F. Alam, D. M. Adams, A. H. Soloway, G. E. Makroglu, O. A. Oredipe, T. E. Blue, and Z. Steplewski, “Conjugation, Purification and Characterization of Boronated Monoclonal Antibodies for Use in Neutron Capture Therapy,” Strahlenther. Onkol., 165 (2/3): 142 (1989).PubMedGoogle Scholar
  21. 21.
    F. Alam, A. H. Soloway, J. E. McGuire, R. E. Barth, W. E. Carey, and D. Adams, “Dicesium N-Succinimidyl 3-(Undecahydro-closo-dodecaboranyldithio) Propionate, a Novel Heterobifunctional Boronating Agent,” J. Med. Chem., 28: 522 (1985).PubMedCrossRefGoogle Scholar
  22. 22.
    Y. Tsukada, Y. Kato, N. Umemoto, Y. Takeda, T. Hara, and H. Hirai, J. Natl. Cancer Inst., 73: 721 (1984).PubMedGoogle Scholar
  23. 23.
    F. Alam, A. H. Soloway, R. F. Barth, and D. M. Adams, “Chemoradiotherapy of Cancer: Boronated Antibodies and Boron Containing Derivatives of Promazine for Neutron Capture Therapy,” in Neutron Capture Therapy, H. Hatanaka, ed., Nishimura Co., Ltd., Niigata, Japan, p. 8 (1986).Google Scholar
  24. 24.
    S. B. Kahl, First Boron USA Workshop, Dallas, Texas, 10–13 April 1988.Google Scholar
  25. 25.
    B. J. Allen, B. J. McGregor, and R. F. Martin, “Neutron Capture Therapy with Gadolinium-157,” Strahlenther. Onkol., 165 (2/3): 156 (1989).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • A. H. Soloway
    • 1
  • F. Alam
    • 1
  • R. F. Barth
    • 1
  • A. K. M. Anisuzzaman
    • 1
  • B. V. Bapat
    • 1
  1. 1.The Ohio State UniversityColumbusUSA

Personalised recommendations